US 11,839,559 B2
Transcatheter heart valve having paravalvular leakage seal
Ali Shahriari, Hillsboro Beach, FL (US)
Assigned to Aortic Innovations, LLC, Hillsboro Beach, FL (US)
Filed by Aortic Innovations, LLC, Hillsboro Beach, FL (US)
Filed on Oct. 28, 2022, as Appl. No. 17/975,986.
Application 14/569,306 is a division of application No. 13/706,896, filed on Dec. 6, 2012, granted, now 8,940,040, issued on Jan. 27, 2015.
Application 17/975,986 is a continuation of application No. 17/213,251, filed on Mar. 26, 2021, granted, now 11,523,918.
Application 17/213,251 is a continuation of application No. 17/096,253, filed on Nov. 12, 2020, granted, now 10,966,846, issued on Apr. 6, 2021.
Application 17/096,253 is a continuation of application No. 17/060,557, filed on Oct. 1, 2020, granted, now 10,888,441, issued on Jan. 12, 2021.
Application 17/060,557 is a continuation of application No. 16/910,189, filed on Jun. 24, 2020, granted, now 10,857,011, issued on Dec. 8, 2020.
Application 16/910,189 is a continuation of application No. 16/808,137, filed on Mar. 3, 2020, granted, now 10,792,172, issued on Oct. 6, 2020.
Application 16/808,137 is a continuation of application No. 16/736,879, filed on Jan. 8, 2020, granted, now 10,842,655, issued on Nov. 24, 2020.
Application 16/736,879 is a continuation of application No. 16/042,286, filed on Jul. 23, 2018, granted, now 10,555,823, issued on Feb. 11, 2020.
Application 16/042,286 is a continuation of application No. 14/614,628, filed on Feb. 5, 2015, granted, now 10,028,848, issued on Jul. 24, 2018.
Application 14/614,628 is a continuation of application No. 14/569,306, filed on Dec. 12, 2014, granted, now 9,339,399, issued on May 17, 2016.
Claims priority of provisional application 61/723,446, filed on Nov. 7, 2012.
Claims priority of provisional application 61/567,458, filed on Dec. 6, 2011.
Prior Publication US 2023/0049107 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 2/856 (2013.01); A61F 2/07 (2013.01); A61F 2/24 (2006.01); A61F 2/82 (2013.01); A61F 2/962 (2013.01); A61F 2/06 (2013.01); A61F 2/89 (2013.01); A61F 2/90 (2013.01); A61F 2/86 (2013.01)
CPC A61F 2/856 (2013.01) [A61F 2/07 (2013.01); A61F 2/2418 (2013.01); A61F 2/82 (2013.01); A61F 2/962 (2013.01); A61F 2/24 (2013.01); A61F 2/86 (2013.01); A61F 2/89 (2013.01); A61F 2/90 (2013.01); A61F 2002/061 (2013.01); A61F 2002/067 (2013.01); A61F 2210/00 (2013.01); A61F 2210/0014 (2013.01); A61F 2210/0057 (2013.01); A61F 2220/0008 (2013.01); A61F 2220/0016 (2013.01); A61F 2220/0025 (2013.01); A61F 2220/0058 (2013.01); A61F 2220/0075 (2013.01); A61F 2230/001 (2013.01); A61F 2230/0034 (2013.01); A61F 2230/0067 (2013.01); A61F 2250/0039 (2013.01); A61F 2250/0048 (2013.01); A61F 2250/0069 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A transcatheter heart valve assembly comprising:
a frame extending around prosthetic heart valve leaflets,
wherein the frame is secured to a covering material by a plurality of stitches,
a sealing material positioned externally to the frame for providing sealing between the frame and a patient's anatomical wall to prevent paravalvular leaks, wherein the sealing material includes a plurality of outwardly extending arcuate fibers that extend outwardly away from the frame, wherein the sealing material is attached to the frame and extends over at least a portion of the frame,
wherein the sealing material is free of a graft covering between the fibers and an outside surface of the frame when the valve assembly is in an undeployed state,
wherein expansion of the valve assembly presses the sealing material against native leaflets of an aorta of the patient,
wherein the valve assembly has a radially compressed orientation and a radially expanded orientation,
wherein the valve assembly is sized and shaped to be delivered endovascularly through a femoral artery of the patient.